Intensive Care Medicine

, Volume 8, Issue 5, pp 215–222 | Cite as

Disturbances of selected plasma proteins in hyperdynamic septic shock

  • J. Witte
  • M. Jochum
  • R. Scherer
  • W. Schramm
  • K. Hochstrasser
  • H. Fritz
Original Articles

Abstract

This study was performed on patients (n=18) suffering from strictly defined hyperdynamic septic shock. Plasma factors (C-reactive protein, acid α1-glycoprotien, fibrinogen, fibrinopeptide A, fibrinogen-fibrin split products, factor XIII, antithrobin III, complement factors C3 and C4, inter-α-trypsin-inhibitor and α2-macroglobulin) measured during hyperdynamic septic shock were highly abnormal. The activation and consumption of clotting, fibrinolytic and complement factors due to system-specific proteinases (such as thrombokinase or plasminogen activators) seemed to be intensified by the nonspecific proteolytic activity of granulocytic proteinases probably released by the action of endotoxins. Possible therapeutic measures to maintain the endogeneous defence mechanism against enhanced proteolysis during septic shock are discussed.

Key words

Septic shock Coagulation Fibrinolytic and complement systems Granulocytic proteinases Nonspecific proteolysis Proteinase inhibitors 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Aasen AO, Ohlsen K (1978) Release of granulocyte elastase in lethal canine endotoxin shock. Hoppe-Seyler's Z Physiol Chem 359:683PubMedGoogle Scholar
  2. 2.
    Aasen AO (1978) Complement activation during subsequent stages of endotoxin shock. Habilitation script, Medical Faculty, Oslo, NorwayGoogle Scholar
  3. 3.
    Alexander JW (1975) Function of leukocytes in defense mechanism. In: Urbaschek B, Urbaschek R, Neter E (eds) Gram negative bacterial infections and mode of endotoxin action. Springer, Wien New York, p 190Google Scholar
  4. 4.
    Friedmann EA (1977) Major problems in obstetrics and gynecology. WB Saunders, Philadelphia London TorontoGoogle Scholar
  5. 5.
    Collen D, Wiman B, Verstraete M (1979) The physiological inhibitors of blood coagulation and fibrinolysis. Elsevier/North-Holland, Biomedical Press, AmsterdamGoogle Scholar
  6. 6.
    Dielt R, Drobinski W, Hochstrasser K (1979) Human inter-α-trypsin-inhibitor-limited proteolysis by trypsin, plasmin, kallikrein and granulocytic elastase and inhibitory properties of the cleavage products. Hoppe Seyler's Z Physiol Chem 360:1313PubMedGoogle Scholar
  7. 7.
    Egbring R, Schmidt W, Fuchs G, Havemann K (1977) Demonstration of granulocytic protheses in plasma of patients with acute leukemia and septicemia with coagulation defects. Blood 49:219PubMedGoogle Scholar
  8. 8.
    Freudenberg N (1978) Endothelium and shock. Path Res Pract 162:105PubMedGoogle Scholar
  9. 9.
    Fritz H (1980) Proteinase inhibitors in severe inflammatory processes (septic shock and experimental endotoxaemia) biochemical, pathophysiological and therapeutic aspects. Ciba Found Symp 75:351Google Scholar
  10. 10.
    Gersmeyer EF, Yasargil EC (1978) Schock und hypotone Kreislaufstörungen. Thieme, StuttgartGoogle Scholar
  11. 11.
    Graeff H, Ernst E, Bocaz JA, v. Hugo R, Hafter R (1976) Evaluation on hypercoagulability in septic abortion. Haemostasis 5:285PubMedGoogle Scholar
  12. 12.
    Hafter R, Petri K, Schiessler H, Graeff H (1980) Vergleich der Spaltungsspezifität von PMV-Leukozytenelastase (LE) und Plasmin gegenüber Fibrinogen, Fibrin und quervernetztem Fibrin. In: Deutsch E, Lechner K (eds) Fibrinolyse, Thrombolyse, Hämostase. Schattauer, Stuttgart New York, p 294Google Scholar
  13. 13.
    Hamilton PJ (1978) Disseminated intravascular coagulation: A review. J Clin Pathology 31:609Google Scholar
  14. 14.
    Havemann K (1978) Neutral proteases of human polymorpho-nuclear leucocytes. Urban & Schwarzenberg, Baltimore MunichGoogle Scholar
  15. 15.
    Heene DL, Lasch HG (1977) Klinische Aspekte der Mikrozir-kulationsstörungen unter besonderer Berücksichtigung des Schocks. In: Altmann HW (ed) Handbuch der Allgemeinen Pathologie, Bd III/7. Springer, Berlin Heidelberg New York, p 889Google Scholar
  16. 16.
    Heimburger N (1975) Proteinase inhibitors of human plasma — their properties and control functions: In: Reiche E, Rifkin DB, Shaw E (eds) Protease and biological control. Cold Spring Harbor Laboratory, p 367Google Scholar
  17. 17.
    Hochstrasser K, Niebel J, Feuth H, Lempart K (1977) Über Abbauprodukte des inter-alpha-Trypsininhibitors in Serum. I. Der Inter-alpha-Trypsininhibitor als Prekursor des säurestabilen Serum-Trypsin-Plasmin-Inhibitors. Klin Wschr 5:337Google Scholar
  18. 18.
    Jochum M, Lander S, Heimburger N, Fritz H (1981) Effect of human granulocytic elastase on isolated human antithrombin III. Hoppe Seyler's Z Physiol Chem 362:103PubMedGoogle Scholar
  19. 18a.
    Jochum M, Witte J, Schiessler H, Selbmann HK, Ruckdeschl G, Fritz H (1981) Clotting and other plasma factors in experimental endotoxinemia: Inhibition of degradation by exogenous proteinase inhibitors. Europ Surg Res 13:152Google Scholar
  20. 19.
    Johnson J, Ohlsson K, Olsson J (1976) Effects of granulocytic neutral proteases on complement components. Scand J Immunol 5:421PubMedGoogle Scholar
  21. 20.
    Lasch HG (1975) Hämorrhagische Diathesen. In: Begemann H (ed) Klinische Hämatologie. Thieme, Stuttgart, p 676Google Scholar
  22. 21.
    Laurell CB (1972) Electroimmunassay. Scand J Clin Lab Invest 29 (Suppl):21Google Scholar
  23. 22.
    Ledgerwood A (1976) Hepatobiliary complications of sepsis. Heart and Lung 5:621PubMedGoogle Scholar
  24. 23.
    Lerner RG, Goldstern R, Gummings G (1977) Endotoxin induced disseminated intravascular clottings: evidence that it is mediated by neutrophil production of tissue factor. Thromb Res 11:253PubMedGoogle Scholar
  25. 24.
    Losowsky MS (1977) Factor XIII. Br J Haematol 37:1PubMedGoogle Scholar
  26. 25.
    Messmer K (1977) Shock, Volumenersatz, Fettembolie. In: Heberer G, Köle W, Tscherne H (eds) Chirugie. Springer, Berlin Heidelberg New York, p 80Google Scholar
  27. 26.
    Nicholson A, Fearon DT, Austen FK (1978) Complement. In: Vane & Ferreira (eds) p 425Google Scholar
  28. 27.
    Ohlsson K (1978) Interaction of granulocyte neutral proteases with alpha1-antitrypsin, alpha2-macroglobulin and alpha1-antichymotrypsin. In: Havemann K, Janoff A (eds) Neutral proteases in human polymorphonuclear leukocytes. Urban & Schwarzenberg, Baltimore MunichGoogle Scholar
  29. 28.
    Putnam FW (1975) The plasma proteins. Academic Press, New York San Francisco LondonGoogle Scholar
  30. 29.
    Rangel DM, Byfield JE, Adomian GE, Stevens GH, Fonkalsrud EW (1970) Hepatic ultrastructural response to endotoxin shock. Surgery 68:503PubMedGoogle Scholar
  31. 30.
    Schiessler H, Kaplan O, Wartenberg S, Witte J (1978) Effect of a protease-inhibitor on the concentration of the fibrin-stabilizing factor XIII in the course of acute gram-negative sepsis. Int Congr Inflammation Bologna/Italy 31.10.-31.11. 1978Google Scholar
  32. 31.
    Schramm W (1977) Diskussion I. In: Marx R; Thies HA (eds) Klinische und ambulante Anwendung klassischer Antikoagulantien. Schattauer, Stuttgart New York, p 139Google Scholar
  33. 32.
    Schramm W, Schmid M, Erhard FW (1977) Radioimmunassay von Fibrinopeptid A: Doppel-Antikörper-Methode. Fortschr Med 19:1291Google Scholar
  34. 33.
    Skansberg P, Cronsberg S, Nilsson JM (1974) The occurrence and significance of fibrin, fibrinogen Degradation products (FDP) in acute infections. Scand J Infect Dis 6:197PubMedGoogle Scholar
  35. 34.
    Starkey PM, Barrett AJ (1977) α1-Macroglobulin, a physiological regulator of proteinase activity}. In: Barrett AJ: (ed) Proteinases in mammalian cells and tissues. North Holland, Amsterdam, p 663Google Scholar

Copyright information

© Springer-Verlag 1982

Authors and Affiliations

  • J. Witte
    • 1
  • M. Jochum
    • 1
  • R. Scherer
    • 5
  • W. Schramm
    • 3
  • K. Hochstrasser
    • 2
  • H. Fritz
    • 4
  1. 1.Department of Surgery, Klinikum GroßhadernUniversity of MunichMunich 70Federal Republic of Germany
  2. 2.Department of ENT-Diseases, Klinikum GroßhadernUniversity of MunichMunich 70Federal Republic of Germany
  3. 3.Department of Internal MedicineUniversity of MunichMunich 70Federal Republic of Germany
  4. 4.Department of Institute of Clinical Chemistry and Clinical BiochemistryUniversity of MunichMartinsriedFederal Republic of Germany
  5. 5.Department of Experimental MedicineMax-Planck-Insitute for BiochemistryMartinsriedFederal Republic of Germany

Personalised recommendations